According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “
A number of other research analysts also recently commented on SELB. ValuEngine raised shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Stifel Nicolaus reaffirmed a “buy” rating and set a $6.00 price objective on shares of Selecta Biosciences in a research report on Friday, August 9th. Finally, Mizuho reaffirmed a “buy” rating and set a $4.00 price objective on shares of Selecta Biosciences in a research report on Sunday. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. Selecta Biosciences currently has an average rating of “Hold” and a consensus target price of $7.88.
Shares of SELB opened at $1.71 on Wednesday. The company’s 50 day moving average is $1.76. Selecta Biosciences has a 52 week low of $1.41 and a 52 week high of $16.55. The stock has a market capitalization of $76.59 million, a P/E ratio of -0.59 and a beta of 1.17.
Selecta Biosciences (NASDAQ:SELB) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.07). The company had revenue of $0.01 million for the quarter. As a group, equities research analysts forecast that Selecta Biosciences will post -1.35 EPS for the current year.
Hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC bought a new stake in Selecta Biosciences in the second quarter worth approximately $31,000. Rhumbline Advisers grew its position in Selecta Biosciences by 43.5% in the first quarter. Rhumbline Advisers now owns 34,158 shares of the company’s stock worth $81,000 after acquiring an additional 10,356 shares in the last quarter. Two Sigma Advisers LP grew its position in Selecta Biosciences by 18.3% in the fourth quarter. Two Sigma Advisers LP now owns 54,900 shares of the company’s stock worth $146,000 after acquiring an additional 8,500 shares in the last quarter. Deutsche Bank AG grew its position in Selecta Biosciences by 251.6% in the fourth quarter. Deutsche Bank AG now owns 127,121 shares of the company’s stock worth $337,000 after acquiring an additional 90,970 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Selecta Biosciences by 17.9% in the fourth quarter. Geode Capital Management LLC now owns 175,308 shares of the company’s stock worth $466,000 after acquiring an additional 26,568 shares in the last quarter. 49.43% of the stock is owned by institutional investors.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.
Featured Story: What are the Benefits of Index Funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.